Benitec Biopharma (Benitec Biopharma) Interest Expense : $-0.02 Mil (TTM As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Benitec Biopharma's interest expense for the three months ended in Mar. 2024 was $ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Benitec Biopharma's Operating Income for the three months ended in Mar. 2024 was $ -4.14 Mil. Benitec Biopharma's Interest Expense for the three months ended in Mar. 2024 was $ -0.00 Mil. Benitec Biopharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Benitec Biopharma Interest Expense Historical Data

The historical data trend for Benitec Biopharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Interest Expense Chart

Benitec Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

-0.01

-0.03

Benitec Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.01	-

Benitec Biopharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

Benitec Biopharma (NAS:BNTC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Benitec Biopharma's Interest Expense for the three months ended in Mar. 2024 was $-0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-4.14 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.06 Mil.

Benitec Biopharma's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Benitec Biopharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Benitec Biopharma (Benitec Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

3940 Trust Way, Hayward, CA, USA, 94545

Website

https://www.benitec.com

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Executives

J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Megan Boston	director, officer: Executive Director	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira	10 percent owner	18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith	director	C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc	10 percent owner	10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis	director	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks	director, officer: Chief Executive Officer	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000